Prostate Cancer Features Archive
More than 90 medical societies have called on the US government to reverse a policy allowing step therapy under Medicare Advantage.
There is a push to create innovative adaptive trial designs that include more patients and, subsequently, more generalizable data.
Interest in these bioengineered antibodies has been rekindled by the striking success seen in the treatment of some cancers with immunotherapies.
A growing body of evidence points to infiltrating myeloid-derived suppressor cells as key players in tumor progression and acquired treatment resistance.
Approximately half of patients with advanced cancer who are enrolled in phase 1 clinical trials do not know the ultimate goal of the study.
The breakdown of the medication abiraterone, which can be accelerated by the presence of a specific gene variant, produces drug metabolites that are suspected to play a role in the progression of prostate cancer to castration-resistant forms of disease.
Some studies suggest triclosan could have oncogenic properties, but more research is needed to confirm a causal link.
Racial minorities are poorly represented in genomic research databases, raising important questions about whether or not all patients will benefit equally from advances in precision oncology.
According to experts, PARP inhibition, radiopharmaceuticals, and immunotherapy could revolutionize how prostate cancer is treated in the coming decade.
New findings bolster the case for the predictive utility of ARID1A mutations.
Liquid Biopsies and Cancer Detection: New Test Assesses Levels of Circulating Proteins for Early-Stage Diagnosis
A new test has been shown to be capable of identifying eight different cancers by assessing levels of circulating proteins along with mutations in cell-free DNA.
Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for Inhibition
Telomerase plays a crucial role in tumor proliferation, and a better understanding of its structure will pave the way for new drug development.
Many clinical trials and systematic reviews note that the use of cannabinoids also comes with adverse events, including a clinical entity that has been gaining evidence in the literature over the last decade called cannabinoid hyperemesis syndrome.
Emerging evidence shows that injecting tumors directly into one tumor can trigger systemic antitumor immunity and immune attacks on untreated tumors elsewhere in the body.
While a recent discovery of a series of communicable cancers has raised concerns, there has been no sign of readily transmittable cancer in people that could spread through a population the way the ones found in other species do.
A recent article is only the latest in a series of studies drawing attention to the importance of diet in prostate cancer development.
Researchers are hotly pursuing 2 distinct biological paths that show remarkable promise in the hunt for an effective anticancer vaccine.
Many HIV-associated cancers develop with the help of oncoviruses — some of which are sexually transmitted.
Knowing that food increases the absorption of some therapies presents the possibility of easily — and significantly — lowering treatment costs.
Results from the Prostate Cancer Prevention Trial indicate that the reduced risk for prostate cancer among men assigned to finasteride continued throughout 16 years of follow-up.
Most tumors do not respond, or evolve resistance, to immune checkpoint inhibition. Now, researchers at Johns Hopkins have engineered a new class of cancer immunotherapy agents designed to short-circuit key mechanisms of tumors' disruption and evasion of immune system attack.
Phase 1 trials should be considered therapeutic options for some patients.
The risk should not discourage patients with cancer from taking these potentially life-extending therapies.
African Americans have a 60% higher incidence of prostate cancer and are about 2 times more likely to die from the disease.
While CDI is becoming more common in all hospitalized patients, patients with cancer appear to be at an elevated risk.
To help curb drug prices, a consortium of hospital groups recently announced plans to form their own nonprofit drug company.
Larotrectinib may have durable antitumor activity in patients with TRK fusion-positive cancers, regardless of tumor type.
The #MeToo movement has inspired many women to relate stories of harassment, and medicine is no exception.
A study could not determine whether one liquid biopsy panel is more accurate than another overall.
The novelty of immunotherapies means that physicians and patients lack extensive experience dealing with them.
New diagnostic and therapeutic tools are in development to inform the management of advanced and metastatic disease.
A recent study is the first to demonstrate the cumulative effect of a large number of lifestyle behaviors.
As oncologists learn to target the immune response to "self and non-self," a delicate therapy balance will eventually be achieved with predictable outcomes, benefits, and toxicity in the fight against cancer.
Hypofractionated radiotherapy's role in postoperative settings remains unclear and awaits outcomes from ongoing studies.
Careful research is needed to ensure that immunotherapies activating T cells do not inadvertently fuel progression of T cell malignancies.
While some researchers are attempting to determine whether cannabis has any anti-tumor activity, the FDA recommends that patients do not listen to websites touting the benefits of cannabidiol.
Researchers hope to define what constitutes a functionally healthy microbiome not just in cancer, but across the health spectrum.
Up to 20% of patients with prostate cancer treated with radiation therapy — external or internal via brachytherapy — will develop radiation colitis.
More evidence may be needed to understand the safety and efficacy of radium-223 in combination with abiraterone or enzalutamide.
The drug addiction strategy must be broadened to account for non-addicted cells, sensitive or resistant, that remain after therapy. Much as selection should favor the development of drug resistant tumor cell lineages, it should also favor lineages that are resistant to addiction.
A class of DUBs known as the ubiquitin-specific-processing proteases are involved in regulating the p53 signaling pathway and have been implicated in tumorigenesis and radiotherapy resistance.
A recent study into the relationship between glucose and cancer cell proliferation may be helping to identify a therapeutic route to starve tumors without killing normal cells.
Socioeconomic status, including education and income level, appears to be tied to prostate-specific antigen test results and prostate cancer treatment and survival, but the exact nature of these associations is not yet clear.
In part 2 of a 2-part series, Bryant Furlow discusses advances in genome sequencing technologies and the resulting insights into associations between inherited germline mutations and cancer.
From anxiety and pain self-management to side effect monitoring in clinical trials, mobile applications are revolutionizing oncology. Researchers say the technology is even transforming clinical trials themselves.
Clifford Pukel, MD, discusses from an immunological standpoint the mysterious phenomenon of spontaneous regression.
Cancer Therapy Advisor asked Dr David Graham and Dr Alexander Kutikov about the state of the science of circulating tumor cell testing in prostate cancer, as well as this emerging field's potential clinical applications.
In part 1 of a 2-part series, Bryant Furlow discusses advances in the understanding of inherited cancer syndromes and screening techniques for early tumor detection in high-risk patients.
Repeated active discussions with patients about distress, treatment options, and goals can both reduce costs and help to identify when aggressive treatment is no longer appropriate, according to hematologist/oncologist Stuart Goldberg, MD.
The lesser toxicity of the 20 mg/m2 dose compared with the 25 mg/m2 dose may benefit frail patients in particular, or those with poor functional status.
While liquid biopsies could prove successful in monitoring treatments, these tests might also find early-stage cancers that, left alone, would never progress.
Increased insurance and clinical trial access, plus diversification of the medical workforce, may help to close treatment gaps.
The race against malware is much the same as a war between an infectious agent and a host: it's a battle between hackers and security experts — and it's not at all clear who is winning.
Mixed data highlight the need for researchers to conduct studies to understand the clinical, rather than just theoretical, risks of HDIs and DDIs.
Active surveillance provides an important alternative to immediate treatment for early-stage, low-risk prostate cancers. For men with a relatively short life expectancy, watchful waiting is recommended.
The US Food and Drug Administration announced a plan to hasten generic drug approvals and thereby increase competition, potentially reducing drug prices altogether.
Circulating megakaryocytes are prognostic among patients with prostate cancer, bolstering evidence from breast cancer studies linking megakaryocytes to metastasis.
If value is hard to define because it is perceived differently by different people, how can oncologists and policymakers accurately gauge cost-effectiveness?
More studies are needed to define the role of intratumoral androgen production and mCRPC resistance to hormonal therapies, and to determine if inhibitors of other steroidogenesis enzymes can be synergistic with abiraterone.
Clinicians are advocating that sexual dysfunction after cancer, which affects a large proportion of survivors, be addressed as a serious quality of life issue.
A recent study suggests that a liquid biopsy may help oncologists to determine which patients with prostate cancer are likely to respond to enzalutamide or abiraterone.
Researchers developed a novel Bayesian adaptive randomization method that maximizes efficiency by focusing the algorithm to reduce uncertainty within patient-treatment baskets.
According to a study across all 32 cancer types, data suggest that 66% of mutations leading to cancer are the result of random events.
Two recent studies provide men diagnosed with localized prostate cancer with important information about the adverse events of treatment choices.
According to the AACI, proposed budget cuts by the White House would likely mean a cut of close to $1 billion for the National Cancer Institute.
Can liquid biopsy and molecular imaging biomarkers help inform more precise management of patients with metastatic prostate cancer?
Dr Clifford Pukel, a board certified medical oncologist and CEO of the Cancer Vaccine Cancer Immunotherapy (CVCI) foundation, discusses some important moments in the history of immunotherapy.
Oncologists, drug developers, and evolutionary theorists could collaborate to design treatments and treatment combinations that are more likely to succeed given the laws of natural selection.
Researchers recently created a tool, Treeomics, to reconstruct the evolutionary pathway of metastases and to chart subclones to their anatomical locations.
Physicians will speak about tumor evolution and AR-indifferent disease at the 2017 ASCO Genitourinary Cancers Symposium in Orlando, Florida.
Scientists are testing immune checkpoint proteins, CD8 T cell clonal expansion, mutational load, and PSA levels as predictive biomarkers for prostate cancer immunotherapy outcomes.
PSA nadir greater than 0.5 ng/mL may serve as a surrogate marker to identify men with localized prostate cancer at high risk of mortality.
Recent discoveries of germline mutations are driving research in novel treatments, including immunotherapies, for prostate cancer.
Researchers are making progress in the search for biomarkers that can help identify which patients are most likely to benefit from radiotherapy.
Rarely, patients with prostate cancer will develop metastases to the gastrointestinal tract, which limit treatment options.
According to the National Cancer Institute, there are not enough available data to establish whether taking vitamin D can prevent cancer.
The pioneer transcription factor GATA2 has been implicated in prostate tumorigenesis, tumor aggressiveness, treatment resistance, and metastasis, making it a promising biomarker.
Dr Barbara Burtness of Yale University's School of Medicine discusses the relationship between happiness and clinical practice in oncology.
A study of self-reported health status shows the need for physicians to consider the overall well-being of pediatric cancer survivors, for life.
Differences between the sexes are known in a variety of cancers, but the reasons remain unclear.
CTA spoke with Judith A. Paice, PhD, RN, to better understand how clinicians are reacting to these legalizations and how she responds to patients asking about cannabis use.
Watson, hoped to be a major source for clinicians, is limited by an inability to interpret clinical trials.
Drugmaker funding for patient advocacy groups might be an important but neglected factor in rising drug prices.
Short, noncoding regulatory stretches of RNA known as microRNA hold promise as prostate cancer biomarkers.
Researchers are trying to develop prostate cancer biomarkers that can predict treatment effects, to spare patients toxicities associated with unhelpful regimens.
Guidelines and technology are changing, but as the number of clinical trials increases, ensuring that trials are reported will be an increasingly difficult task.
Proponents of competing evolutionary theories seek to explain—and combat—oncogenesis.
Financial hardship is common among cancer survivors in the US, and can be a psychologically and economically debilitating burden.
This inexpensive, web-based treatment may help patients overcome cognitive issues from chemotherapy.
Educating the public about risk factors and prevention strategies remains a major challenge to cancer prevention.
Embracing all the myriad variations of the human genome should, in theory, lead to rewards that all can share.
Researchers are identifying new roles for infectious and commensal microbes in facilitating and inhibiting carcinogenesis.
Prostate-specific antigen screening is not meaningfully less frequent than before guidelines were issued against use of the test.
At War on Cancer, numerous figures in cancer care discussed innovations to reduce the costs associated with drugs.
After a litany of failures for immunotherapies against prostate cancer, calls are mounting for approaches that combine these agents with other treatments.
Contrary to some news headlines, monitoring prostate cancer has different survival implications than treatment after 10 years.
In this Q&A, CTA asked Dr Pal about the ongoing controversy, evidence base, and pivotal studies of intermittent versus continuous androgen deprivation therapy for prostate cancer.
Speakers at the 2016 Concordia Summit's panel, "Precision Medicine in Cancer Research," discussed the importance and future of immunotherapy for cancer treatment.
In this question-and-answer session, CTA asked Dr Carroll about CRISPR-Cas9, the state of the science of genome editing, and its implications for oncology.
CRISPR is receiving attention as a gene-editing tool that may help us treat cancer, but evolutionary theory suggests a much more complex reality.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Plastics and Cancer
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Emetogenic Potential of Antineoplastic Agents
- 20-Year Data Link High-Dose Chemotherapy and Hematopoietic Stem Cell Transplant to Survival Benefit in High-Risk Early Breast Cancer
- Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
- Reducing Trastuzumab Duration Lowers Costs by Nearly £10,000 in HER2-positive Breast Cancer
- Resistance Mechanisms Identified for NSCLC Progression With First-Line Osimertinib
- Atezolizumab and Nab-Paclitaxel Prolonged PFS in Metastatic Triple-Negative Breast Cancer